Healthcare provider profile · identity verified

Mikhail Eiseler, DO

Family Practice · MEQUON, WI · NPI 1568843696

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	504	162
Losartan Potassium	Losartan Potassium	439	120
Amlodipine Besylate	Amlodipine Besylate	389	113
Levothyroxine Sodium	Levothyroxine Sodium	361	81
Rosuvastatin Calcium	Rosuvastatin Calcium	289	87
Lisinopril	Lisinopril	258	79
Metoprolol Succinate	Metoprolol Succinate	219	74
Simvastatin	Simvastatin	214	68
Omeprazole	Omeprazole	195	59
Pantoprazole Sodium	Pantoprazole Sodium	190	59
Metformin Hcl	Metformin Hcl	178	49
Allopurinol	Allopurinol	166	55
Hydrochlorothiazide	Hydrochlorothiazide	157	55
Metformin Hcl Er	Metformin Hcl	149	41
Eliquis	Apixaban	147	29
Gabapentin	Gabapentin	144	42
Trazodone Hcl	Trazodone Hcl	125	35
Tamsulosin Hcl	Tamsulosin Hcl	120	36
Zolpidem Tartrate	Zolpidem Tartrate	117	27
Carvedilol	Carvedilol	109	31
Duloxetine Hcl	Duloxetine Hcl	99	22
Pravastatin Sodium	Pravastatin Sodium	93	29
Alprazolam	Alprazolam	89	19
Furosemide	Furosemide	88	34
Metoprolol Tartrate	Metoprolol Tartrate	86	21
Olmesartan Medoxomil	Olmesartan Medoxomil	79	34
Albuterol Sulfate Hfa	Albuterol Sulfate	76	30
Montelukast Sodium	Montelukast Sodium	76	21
Sertraline Hcl	Sertraline Hcl	76	22
Venlafaxine Hcl Er	Venlafaxine Hcl	76	18
Clopidogrel	Clopidogrel Bisulfate	74	21
Fluoxetine Hcl	Fluoxetine Hcl	72	17
Finasteride	Finasteride	69	19
Lorazepam	Lorazepam	67	14
Donepezil Hcl	Donepezil Hcl	60	suppressed
Xarelto	Rivaroxaban	60	13
Tramadol Hcl	Tramadol Hcl	57	15
Jardiance	Empagliflozin	54	11
Fluticasone Propionate	Fluticasone Propionate	53	19
Atenolol	Atenolol	49	17
Hydroxyzine Hcl	Hydroxyzine Hcl	49	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	18
Spironolactone	Spironolactone	49	16
Chlorthalidone	Chlorthalidone	48	16
Mirtazapine	Mirtazapine	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	45	15
Glipizide	Glipizide	45	14
Potassium Chloride	Potassium Chloride	45	19
Alendronate Sodium	Alendronate Sodium	44	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	13
Warfarin Sodium	Warfarin Sodium	43	17
Pregabalin	Pregabalin	41	suppressed
Famotidine	Famotidine	40	16
Valsartan	Valsartan	39	12
Hydralazine Hcl	Hydralazine Hcl	38	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	13
Memantine Hcl	Memantine Hcl	37	suppressed
Celecoxib	Celecoxib	36	suppressed
Glipizide Er	Glipizide	36	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	suppressed
Clonazepam	Clonazepam	34	suppressed
Levetiracetam	Levetiracetam	34	suppressed
Lovastatin	Lovastatin	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	11
Diclofenac Sodium	Diclofenac Sodium	33	suppressed
Propranolol Hcl	Propranolol Hcl	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	23
Diazepam	Diazepam	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	29	suppressed
Prednisone	Prednisone	29	23
Bupropion Xl	Bupropion Hcl	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	14
Terazosin Hcl	Terazosin Hcl	26	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Meloxicam	Meloxicam	23	suppressed
Acarbose	Acarbose	21	suppressed
Irbesartan	Irbesartan	21	suppressed
Latanoprost	Latanoprost	21	suppressed
Megestrol Acetate	Megestrol Acetate	21	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Digoxin	Digoxin	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	16	suppressed
Spiriva Handihaler	Tiotropium Bromide	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Ozempic	Semaglutide	13	suppressed
Zaleplon	Zaleplon	13	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	12	suppressed
Benicar	Olmesartan Medoxomil	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Naproxen	Naproxen	11	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	11	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error